Hansoh Pharma Partners with Chinese Anti-Cancer Association to Advance Oncology Education and Standardized Treatment

Recently, the 2024 China Conference on Holistic Integrative Oncology (CCHIO), hosted by the Chinese Anti-Cancer Association, was held in Xi'an. During the conference, the launch ceremonies for the "Prostate Cancer Diagnosis and Treatment Popular Science Book" and the "2025 CACA Guidelines China Tour - Unlimited Joy Grassroots Tour," both supported by Hansoh Pharma, were successively held. Hansoh Pharma also participated in the concurrently held "China Cancer Prevention and Control Awareness Week and the 4th CACA Guidelines Forum on Safe Medication for Cancer," offering advice and suggestions on safe cancer medication.

With the acceleration of modern life节奏 and changes in environmental factors, the incidence and mortality of prostate cancer continue to rise. To help patients systematically understand the disease and raise public awareness, Hansoh Pharma, in collaboration with the Urology and Science Popularization Committees of the Chinese Anti-Cancer Association, jointly launched the compilation of "The Prostate Cancer Diagnosis and Treatment Popular Science Answer Book" at the CCHIO conference on November 16.

This popular science book will fully leverage the professional expertise of scholars and experts, breaking down complex knowledge about prostate cancer into easy-to-understand Q&As. It will help patients form a correct understanding of the disease and master methods for daily disease management, improving overall treatment outcomes and patients' quality of life.

Lung cancer is the malignant tumor with the highest incidence and mortality rate in China, and it is also a key area where Hansoh Pharma collaborates with the Chinese Anti-Cancer Association (CACA) to promote standardized diagnosis and treatment. On November 17, the "2025 CACA Guidelines China Tour - Melotinib Grassroots Initiative," guided by the Chinese Anti-Cancer Association and jointly launched by the CACA Media Communication Committee and the CACA Science Popularization Committee, with public welfare support from Hansoh Pharma, officially kicked off at this year's CCHIO conference.

Since its launch in 2024, the project has been guided by the *Chinese Guidelines for Integrated Diagnosis and Treatment of Tumors (CACA)*, focusing on the integrated thinking of "prevention, screening, integration, treatment, and rehabilitation" to explore standardized diagnosis and treatment of lung cancer in depth. Through case sharing, lectures, commentary, ward rounds, and other activities, experts have provided a platform for academic exchange and learning for participating physicians, effectively enhancing the lung cancer diagnosis and treatment capabilities of grassroots medical personnel.

In recognition of its outstanding contributions to the promotion of CACA guidelines and the interpretation of core popular science knowledge, Hansoh Pharma, the supporting party of the "CACA Guidelines China Tour - Unlimited Joy Grassroots Initiative" project, was awarded the "2024 Science Popularization Benefit Demonstration Unit" at this year’s CCHIO conference.